MET amplification (bypass resistance)
When lung cancer switches on the MET receptor to bypass a blocked EGFR pill.
MET amplification occurs in ~15-20% of osimertinib-resistant tumours. Rationale for amivantamab (EGFR×MET), MARIPOSA's combination approach, MET TKI add-on trials (INSIGHT 2, SAVANNAH), and c-MET ADCs.
Pages like this
not linked directly; found by shared links- TermEGFR C797S
Shares Amivantamab + lazertinib (first-line EGFR NSCLC), Resistance routes: how a blocked pathway comes back, Receptor tyrosine kinase activation, Drug resistance (primary and acquired).
- TrialMARIPOSA
Shares Amivantamab + lazertinib (first-line EGFR NSCLC), Amivantamab, MET, Acquired resistance to every therapy.
- IdeaAdd a drug when the blood test turns, without stopping the one that works
Shares Amivantamab, MET, Acquired resistance to every therapy, EGFR.
- TrialTeliMET NSCLC-01
Shares Telisotuzumab vedotin, MET, Non-small-cell lung cancer.
- IdeaAdd the second drug on day one when the escape route is predictable
Shares Amivantamab, MET, Acquired resistance to every therapy, EGFR.
- TermEGFR exon 20 insertion
Shares Amivantamab, Receptor tyrosine kinase activation, EGFR, Non-small-cell lung cancer.
- PersonDae Ho Lee
Shares Amivantamab, MET, EGFR, Non-small-cell lung cancer.
- ProductLazertinib
Shares Amivantamab + lazertinib (first-line EGFR NSCLC), Amivantamab, EGFR, Non-small-cell lung cancer.